Goldman Sachs Call 200 MRK 21.03..../ DE000GJ3K6Y4 /
24/01/2025 09:00:30 | Chg.0.000 | Bid15:53:25 | Ask15:53:25 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.020EUR | 0.00% | 0.020 Bid Size: 20,000 |
0.040 Ask Size: 20,000 |
Merck and Co Inc | 200.00 USD | 21/03/2025 | Call |
GlobeNewswire
31/07/2024
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
GlobeNewswire
17/07/2024
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease a...
GlobeNewswire
11/06/2024
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next...
GlobeNewswire
06/06/2024
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...
GlobeNewswire
28/05/2024
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
GlobeNewswire
23/05/2024
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
GlobeNewswire
16/05/2024
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
14/05/2024
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewswire
08/05/2024
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
24/04/2024
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Onc...
GlobeNewswire
15/04/2024
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness